Key result
Memopart PFO occluder achieves ~100% procedural success with no significant safety complications.
Why the study?
Safety and efficacy data for percutaneous closure of complex PFO anatomies using the Memopart occluder device were needed.
Does percutaneous closure using the Memopart PFO occluder device effectively and safely treat complex patent foramen ovale anatomies?
Observational (n=10)
No
Does percutaneous closure using the Memopart PFO occluder device effectively and safely treat complex patent foramen ovale anatomies?
The Memopart PFO occluder appears to be a safe and effective device for closing complex PFO anatomies with high procedural success and low residual shunt rates.
Answers are grounded in this paper and cite their sources.
Supports feasibility in complex PFO; hypothesis-generating and requires prospective validation before practice change.
We conducted a single center observational study aimed to assess safety and efficacy of Balmed Memopart PFO occluder in treatment of complex PFO anatomies including at least one of the following: tunnel length ≥ 8 mm, atrial septal aneurysm, lipomatous hypertrophy of fossa ovalis rims (≥10 mm), cribriform or additional multiple small defects on the fossa ovalis, residual large Eustachian ridge or Chiari network. This analysis demonstrated Memopart PFO occluder device to be a safe and effective option for PFO closure, with good procedural success rate (100 %) and no significant safety issues (1 mild residual shunt at 24 h).
No takes yet. Share an insight, caveat, or question.
Gili et al. (2025) conducted an observational in Patent foramen ovale (PFO) with complex anatomy (n=10). Memopart PFO occluder was evaluated on Procedural success. The Memopart PFO occluder achieved a 100% procedural success rate without significant safety complications, resulting in only a 10% rate of mild residual shunt at 24 hours.
Synapse has enriched 10 related papers. Consider them for comparative context: